Home › Companies › AKEBIA THERAPEUTICS INC. › 2023-2024
At AKEBIA THERAPEUTICS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 71 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 207 separate fund positions. On the most widely held item on that ballot — Hold an advisory vote on the compensation of Akebia's named executive officers; — AKEBIA THERAPEUTICS INC.'s filing reports the proposal as approved, with 50.8% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AKEBIA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AKEBIA THERAPEUTICS INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 6, 2024: 6 items on AKEBIA THERAPEUTICS INC.’s Form 8-K, filed June 10, 2024: 2 approved · 1 not approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore AKEBIA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are AKEBIA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Ronald E. Frieson | 60,670,984 | -- | -- | 37,772,419 | 38,195,337 | 62% | Not verified | — |
| Elect Director: Steven C. Gilman, Ph.D. | 67,980,247 | -- | -- | 30,463,156 | 38,195,337 | 69% | Not verified | — |
| Elect Director: Cynthia Smith | 67,799,627 | -- | -- | 30,643,776 | 38,195,337 | 69% | Not verified | — |
| 2. Proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 9,800,000 shares | 45,155,875 | 52,820,792 | 466,736 | -- | 38,195,337 | 46.1% | Not approved | — |
| 3. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers | 48,857,959 | 47,361,877 | 2,223,567 | -- | 38,195,337 | 50.8% | Approved | — |
| 4. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 120,235,723 | 13,578,974 | 2,824,043 | -- | -- | 90% | Approved | — |
Source: AKEBIA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
Each item below shows how the 71 asset managers that disclosed a AKEBIA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Description as filed by funds: Elect three Class I directors to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Cynthia Smith
AKEBIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Cynthia Smith”): 67,799,627 for, 30,643,776 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 8,607,250 for, 138,213 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,963,175 | 0 | 0 | 0 | For |
| Fidelity | 1,445,326 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 0 | 0 | 138,213 | Withhold |
| Russell Investments | 82,376 | 0 | 0 | 0 | For |
| Charles Schwab | 79,804 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 17,028 | 0 | 0 | 0 | For |
| Victory Capital | 12,417 | 0 | 0 | 0 | For |
| John Hancock | 2,951 | 0 | 0 | 0 | For |
| Nationwide | 2,285 | 0 | 0 | 0 | For |
| Guggenheim | 1,039 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 514 | 0 | 0 | 0 | For |
| Invesco | 335 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
62% Majority: yes · of votes cast
Description as filed by funds: Elect three Class I directors to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Ronald E. Frieson
AKEBIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ronald E. Frieson”): 60,670,984 for, 37,772,419 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 62% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 8,726,436 for, 16,076 withheld, 2,951 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,963,175 | 0 | 0 | 0 | For |
| Fidelity | 1,445,326 | 0 | 0 | 0 | For |
| Federated Hermes | 138,213 | 0 | 0 | 0 | For |
| Russell Investments | 82,376 | 0 | 0 | 0 | For |
| Charles Schwab | 79,804 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 17,028 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 12,417 | Withhold |
| John Hancock | 0 | 0 | 2,951 | 0 | Abstain |
| Nationwide | 0 | 0 | 0 | 2,285 | Withhold |
| Guggenheim | 0 | 0 | 0 | 1,039 | Withhold |
| Advisors' Inner Circle Fund III | 514 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 335 | Withhold |
Combines 4 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Description as filed by funds: Elect three Class I directors to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Steven C. Gilman
AKEBIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Steven C. Gilman, Ph.D.”): 67,980,247 for, 30,463,156 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 8,607,250 for, 138,213 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,963,175 | 0 | 0 | 0 | For |
| Fidelity | 1,445,326 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 0 | 0 | 138,213 | Withhold |
| Russell Investments | 82,376 | 0 | 0 | 0 | For |
| Charles Schwab | 79,804 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 17,028 | 0 | 0 | 0 | For |
| Victory Capital | 12,417 | 0 | 0 | 0 | For |
| John Hancock | 2,951 | 0 | 0 | 0 | For |
| Nationwide | 2,285 | 0 | 0 | 0 | For |
| Guggenheim | 1,039 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 514 | 0 | 0 | 0 | For |
| Invesco | 335 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
46.1% Not approved · of votes cast
Description as filed by funds: Approve an amendment to the Akebia Therapeutics, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 9,800,000 shares;
AKEBIA THERAPEUTICS INC.’s own tally for this item (“2. Proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 9,800,000 shares”): 45,155,875 for, 52,820,792 against — failed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The proposal to approve an amendment to the Company's 2023 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 9,800,000 shares was not approved as follows:”
Support: 46.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 8,755,463 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,963,175 | 0 | 0 | 0 | For |
| Fidelity | 1,445,326 | 0 | 0 | 0 | For |
| Federated Hermes | 138,213 | 0 | 0 | 0 | For |
| Russell Investments | 82,376 | 0 | 0 | 0 | For |
| Charles Schwab | 79,804 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 17,028 | 0 | 0 | 0 | For |
| Victory Capital | 12,417 | 0 | 0 | 0 | For |
| GRIMES & COMPANY, INC. | 10,000 | 0 | 0 | 0 | For |
| John Hancock | 2,951 | 0 | 0 | 0 | For |
| Nationwide | 2,285 | 0 | 0 | 0 | For |
| Guggenheim | 1,039 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 514 | 0 | 0 | 0 | For |
| Invesco | 335 | 0 | 0 | 0 | For |
Combines 9 wordings of this item as funds reported it.
50.8% Approved · of votes cast
Description as filed by funds: Hold an advisory vote on the compensation of Akebia's named executive officers;
AKEBIA THERAPEUTICS INC.’s own tally for this item (“3. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers”): 48,857,959 for, 47,361,877 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers was approved as follows:”
Support: 50.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,963,175 | 0 | 0 | 0 | For |
| Fidelity | 1,445,326 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 138,213 | 0 | 0 | Against |
| Russell Investments | 0 | 82,376 | 0 | 0 | Against |
| Charles Schwab | 79,804 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 17,028 | 0 | 0 | 0 | For |
| Victory Capital | 12,417 | 0 | 0 | 0 | For |
| John Hancock | 2,951 | 0 | 0 | 0 | For |
| Nationwide | 2,285 | 0 | 0 | 0 | For |
| Guggenheim | 1,039 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 514 | 0 | 0 | 0 | For |
| Invesco | 335 | 0 | 0 | 0 | For |
Fund voting reports, all 12 managers: 8,524,874 for, 220,589 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,993,741 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 1,827,265 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1,537,672 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 1,372,719 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,178,447 | 0 | 0 | 0 | For |
| Renaissance | 1,135,240 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 999,961 | 0 | 0 | 0 | For |
| Point72 | 457,261 | 0 | 0 | 0 | For |
| Fidelity | 436,743 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 327,520 | 0 | 0 | Against |
| BANK OF AMERICA NA | 0 | 220,864 | 0 | 0 | Against |
| Citadel | 206,314 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 198,539 | 0 | 0 | Against |
| Northern Trust | 169,706 | 0 | 0 | 0 | For |
| EAM Investors, LLC | 154,311 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 142,492 | 0 | 0 | Against |
| Charles Schwab | 79,804 | 0 | 0 | 0 | For |
| OMERS ADMINISTRATION Corp | 77,000 | 0 | 0 | 0 | For |
| State Street | 73,393 | 0 | 0 | 0 | For |
| T. Rowe Price | 59,900 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 45,380 | 0 | 0 | Against |
| Lazard | 44,156 | 0 | 0 | 0 | For |
| Goldman Sachs | 40,841 | 0 | 0 | 0 | For |
| TD ASSET MANAGEMENT INC | 40,553 | 0 | 0 | 0 | For |
| Graham Capital Management, L.P. | 36,269 | 0 | 0 | 0 | For |
Institutional-manager reports, all 67 managers: 12,098,550 for, 1,008,776 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
90% Approved · of votes cast
Description as filed by funds: Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and
AKEBIA THERAPEUTICS INC.’s own tally for this item (“4. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 120,235,723 for, 13,578,974 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved as follows:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 8,744,949 for, 514 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,963,175 | 0 | 0 | 0 | For |
| Fidelity | 1,445,326 | 0 | 0 | 0 | For |
| Federated Hermes | 138,213 | 0 | 0 | 0 | For |
| Russell Investments | 82,376 | 0 | 0 | 0 | For |
| Charles Schwab | 79,804 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 17,028 | 0 | 0 | 0 | For |
| Victory Capital | 12,417 | 0 | 0 | 0 | For |
| John Hancock | 2,951 | 0 | 0 | 0 | For |
| Nationwide | 2,285 | 0 | 0 | 0 | For |
| Guggenheim | 1,039 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 514 | 0 | 0 | Against |
| Invesco | 335 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 209,596,378 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.32% |
| 2 | Fidelity | 0.69% |
| 3 | Federated Hermes | 0.07% |
| 4 | Russell Investments | 0.04% |
| 5 | Charles Schwab | 0.04% |
| 6 | MASTER INVESTMENT PORTFOLIO | <0.01% |
| 7 | Victory Capital | <0.01% |
| 8 | John Hancock | <0.01% |
| 9 | Nationwide | <0.01% |
| 10 | Guggenheim | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 0.95% |
| 2 | Ensign Peak Advisors, Inc | 0.87% |
| 3 | JACOBS LEVY EQUITY MANAGEMENT, INC | 0.73% |
| 4 | ACADIAN ASSET MANAGEMENT LLC | 0.65% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.56% |
| 6 | Renaissance | 0.54% |
| 7 | Connor, Clark & Lunn Investment Management Ltd. | 0.48% |
| 8 | Point72 | 0.22% |
| 9 | Fidelity | 0.21% |
| 10 | MARSHALL WACE, LLP | 0.16% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 8.97% | 13F |
| Muneer A. Satter | 7.73% | DEF14A |
| Vanguard Group | 7.42% | 13F |
| Satter Muneer A | 2.74% | 13G |
| Morgan Stanley | 2.06% | 13F |
| John P. Butler | 1.95% | DEF14A |
| Renaissance Technologies | 1.74% | 13F |
| Millennium Management | 1.56% | 13F |
| Geode Capital | 0.87% | 13F |
| Goldman Sachs | 0.84% | 13F |
Percentages above are of 209,596,378 shares outstanding, as reported by AKEBIA THERAPEUTICS INC. on its Form 10-Q dated May 7, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AKEBIA THERAPEUTICS INC.’s 10-Q dated May 7, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
AKEBIA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “AKEBIA THERAPEUTICS (AKBA) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/akebia-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.